Cerevel Therapeutics Holdings Inc reports results for the quarter ended in September - Earnings Summary

Cerevel Therapeutics Holdings

01/11/2023 13:31

* Cerevel Therapeutics Holdings Inc  CERE.OQ  reported a
quarterly
adjusted loss of 61 cents​​ per share for the quarter ended in
September, higher than the same quarter last year, when the
company reported EPS of -66 cents.  The mean expectation of
nine analysts for the quarter was for a loss of 63 cents per
share. Wall Street expected results to range from -72 cents
to -44 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Cerevel Therapeutics Holdings Inc's reported EPS for the
quarter
was a loss of 61 cents​.
    * The company reported a quarterly loss of $96.36 million.
    * Cerevel Therapeutics Holdings Inc shares had risen by 8.3%
this
quarter and lost 25.0% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 4.6%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," 4
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for Cerevel
Therapeutics Holdings Inc is $33.00 
This summary was machine generated from LSEG data November 1 at
01:31 p.m. UTC. ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2023      -0.63          -0.61          Beat
 Jun. 30 2023      -0.65          -0.63          Beat
 Mar. 31 2023      -0.67          -0.67          Met
 Dec. 31 2022      -0.64          -0.59          Beat